UNSPSC 51362404: Homofenazine

This classification denotes a sedative and hypnotic with the molecular formula C23H28F3N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PEL7G6VRZ2, chemically known as 2-trifluoroethyl-10-(3-(4-(beta-hydroxyethyl-1-hexahydro-1,4-diazepinyl)propyl)phenothiazine but generally known as homofenazine, which bears US NIH Compound Identifier 19687. European Medicines Agency schedules Homofenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08051MIG.

UNSPSC 51362404 Homofenazine is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity under this code does not align with homofenazine as a discrete product. Instead, state and local buyers are procuring naloxone, safe drug deactivation systems, and broader pharmaceutical supply arrangements that fall outside homofenazine's scope. The code shows little relevant recent activity that directly matches its intended pharmaceutical category.

The most recent opportunity tagged to this code is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 with a bid deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; bidders must include all shipping and delivery costs and meet E-Verify compliance and drug-free workplace certification requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program serving state pharmacy benefit programs. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing evaluations weighted 75 percent on competitiveness and awards effective July 1, 2026. These opportunities reflect procurement of naloxone opioid reversal agents, drug deactivation systems, and generic pharmaceutical supply chains rather than homofenazine specifically. The code's nominal scope and actual recent procurement activity diverge significantly; a business development professional evaluating homofenazine supply should verify whether this UNSPSC assignment is accurate before pursuing opportunities under it.